These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Leukemia AND MAP2K1, MAPKK1, 5604, ENSG00000169032, Q02750, MEK1, MKK1, PRKMK1
282 results:

  • 1. Efficacy of the Allosteric MEK Inhibitor Trametinib in Relapsed and Refractory Juvenile Myelomonocytic leukemia: a Report from the Children's Oncology Group.
    Stieglitz E; Lee AG; Angus SP; Davis C; Barkauskas DA; Hall D; Kogan SC; Meyer J; Rhodes SD; Tasian SK; Xuei X; Shannon K; Loh ML; Fox E; Weigel BJ
    Cancer Discov; 2024 Sep; 14(9):1590-1598. PubMed ID: 38867349
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Dachshund Homolog 1: Unveiling Its Potential Role in Megakaryopoiesis and
    Lin GL; Chang HH; Lin WT; Liou YS; Lai YL; Hsieh MH; Chen PK; Liao CY; Tsai CC; Wang TF; Chu SC; Kau JH; Huang HH; Hsu HL; Sun DS
    Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542074
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. The effect of STAT1, miR-99b, and map2k1 in alcoholic liver disease (ALD) mouse model and hepatocyte.
    Du H; Yu H; Zhou M; Hui Q; Hou Y; Jiang Y
    Aging (Albany NY); 2024 Feb; 16(5):4224-4235. PubMed ID: 38431286
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Liquid biopsy-based circulating tumour (ct)DNA analysis of a spectrum of myeloid and lymphoid malignancies yields clinically actionable results.
    Mata DA; Lee JK; Shanmugam V; Marcus CB; Schrock AB; Williams EA; Ritterhouse LL; Hickman RA; Janovitz T; Patel NR; Kroger BR; Ross JS; Mirza KM; Oxnard GR; Vergilio JA; Elvin JA; Benhamida JK; Decker B; Xu ML
    Histopathology; 2024 Jun; 84(7):1224-1237. PubMed ID: 38422618
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Phase 2 study using low dose cytarabine for adult patients with newly diagnosed Langerhans cell histiocytosis.
    Chang L; Lang M; Lin H; Cai H; Duan MH; Zhou DB; Cao XX
    Leukemia; 2024 Apr; 38(4):803-809. PubMed ID: 38388646
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b Trial.
    Konopleva MY; Dail M; Daver NG; Garcia JS; Jonas BA; Yee KWL; Kelly KR; Vey N; Assouline S; Roboz GJ; Paolini S; Pollyea DA; Tafuri A; Brandwein JM; Pigneux A; Powell BL; Fenaux P; Olin RL; Visani G; Martinelli G; Onishi M; Wang J; Huang W; Dunshee DR; Hamidi H; Ott MG; Hong WJ; Andreeff M
    Clin Lymphoma Myeloma Leuk; 2024 Jun; 24(6):364-374. PubMed ID: 38378362
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Properties of FDA-approved small molecule protein kinase inhibitors: A 2024 update.
    Roskoski R
    Pharmacol Res; 2024 Feb; 200():107059. PubMed ID: 38216005
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. High In Vitro and In Vivo Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models.
    Vuaroqueaux V; Musch A; Peille AL; Kelter G; Weichert L; Metz T; Hendriks HR; Fiebig HH
    Cancer Res Commun; 2023 Oct; 3(10):2170-2181. PubMed ID: 37830744
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. The clinical and molecular taxonomy of t(14;18)-negative follicular lymphomas.
    Salaverria I; Weigert O; Quintanilla-Martinez L
    Blood Adv; 2023 Sep; 7(18):5258-5271. PubMed ID: 37561599
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. The cardiac glycoside ZINC253504760 induces parthanatos-type cell death and G2/M arrest via downregulation of mek1/2 phosphorylation in leukemia cells.
    Zhou M; Boulos JC; Klauck SM; Efferth T
    Cell Biol Toxicol; 2023 Dec; 39(6):2971-2997. PubMed ID: 37322258
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. A case report of a blueberry muffin baby caused by congenital self-healing indeterminate cell histiocytosis.
    Koster SBL; Vinke ME; van den Bos C; van Heel WJM; Kranendonk MEG; Natté R; van Tuyll van Serooskerken AM
    BMC Pediatr; 2023 Mar; 23(1):111. PubMed ID: 36890472
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Properties of FDA-approved small molecule protein kinase inhibitors: A 2023 update.
    Roskoski R
    Pharmacol Res; 2023 Jan; 187():106552. PubMed ID: 36403719
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Identification of cell type-specific correlations between ERK activity and cell viability upon treatment with ERK1/2 inhibitors.
    Lebedev TD; Khabusheva ER; Mareeva SR; Ivanenko KA; Morozov AV; Spirin PV; Rubtsov PM; Snezhkina AV; Kudryavtseva AV; Sorokin MI; Buzdin AA; Prassolov VS
    J Biol Chem; 2022 Aug; 298(8):102226. PubMed ID: 35787369
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. TRAF3 alterations are frequent in del-3'IGH chronic lymphocytic leukemia patients and define a specific subgroup with adverse clinical features.
    Pérez-Carretero C; Hernández-Sánchez M; González T; Quijada-Álamo M; Martín-Izquierdo M; Santos-Mínguez S; Miguel-García C; Vidal MJ; García-De-Coca A; Galende J; Pardal E; Aguilar C; Vargas-Pabón M; Dávila J; Gascón-Y-Marín I; Hernández-Rivas JÁ; Benito R; Hernández-Rivas JM; Rodríguez-Vicente AE
    Am J Hematol; 2022 Jul; 97(7):903-914. PubMed ID: 35472012
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. B-cell receptor signaling induces proteasomal degradation of PDCD4 via mek1/2 and mTORC1 in malignant B cells.
    Taylor J; Wilmore S; Marriot S; Rogers-Broadway KR; Fell R; Minton AR; Branch T; Ashton-Key M; Coldwell M; Stevenson FK; Forconi F; Steele AJ; Packham G; Yeomans A
    Cell Signal; 2022 Jun; 94():110311. PubMed ID: 35306137
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Selumetinib in combination with dexamethasone for the treatment of relapsed/refractory RAS-pathway mutated paediatric and adult acute lymphoblastic leukaemia (SeluDex): study protocol for an international, parallel-group, dose-finding with expansion phase I/II trial.
    Menne T; Slade D; Savage J; Johnson S; Irving J; Kearns P; Plummer R; Shenton G; Veal GJ; Vormoor B; Vormoor J; Billingham L
    BMJ Open; 2022 Mar; 12(3):e059872. PubMed ID: 35246426
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Advances in the Treatment of Hairy Cell leukemia Variant.
    Tran J; Gaulin C; Tallman MS
    Curr Treat Options Oncol; 2022 Jan; 23(1):99-116. PubMed ID: 35178674
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. ABT199/venetoclax potentiates the cytotoxicity of alkylating agents and fludarabine in acute myeloid leukemia cells.
    Valdez BC; Murray D; Yuan B; Nieto Y; Popat U; Andersson BS
    Oncotarget; 2022; 13():319-330. PubMed ID: 35154579
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Fine-tuning of MEK signaling is pivotal for limiting B and T cell activation.
    Houde N; Beuret L; Bonaud A; Fortier-Beaulieu SP; Truchon-Landry K; Aoidi R; Pic É; Alouche N; Rondeau V; Schlecht-Louf G; Balabanian K; Espéli M; Charron J
    Cell Rep; 2022 Jan; 38(2):110223. PubMed ID: 35021072
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Properties of FDA-approved small molecule protein kinase inhibitors: A 2022 update.
    Roskoski R
    Pharmacol Res; 2022 Jan; 175():106037. PubMed ID: 34921994
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 15.